149 related articles for article (PubMed ID: 26660639)
1. Do low-dose anti-TNF regimens have a role in patients with ankylosing spondylitis?
Yates M; Keat A; Gaffney K
Rheumatology (Oxford); 2016 May; 55(5):769-72. PubMed ID: 26660639
[No Abstract] [Full Text] [Related]
2. Maintenance of Low Disease Activity following Tumor Necrosis Factor Inhibitor Dose Tapering in Ankylosing Spondylitis.
Steel L; Gaffney K
J Rheumatol; 2017 Aug; 44(8):1292. PubMed ID: 28765347
[No Abstract] [Full Text] [Related]
3. Switching anti-TNF therapy in ankylosing spondylitis.
Pradeep DJ; Keat AC; Gaffney K; Brooksby A; Leeder J; Harris C
Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
[No Abstract] [Full Text] [Related]
4. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
Jois RN; Gaffney K; Keat A
Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
[No Abstract] [Full Text] [Related]
5. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study.
Cantini F; Niccoli L; Benucci M; Chindamo D; Nannini C; Olivieri I; Padula A; Salvarani C
Arthritis Rheum; 2006 Oct; 55(5):812-6. PubMed ID: 17013842
[No Abstract] [Full Text] [Related]
6. Predictors of response to tumor necrosis factor-alpha blockers in ankylosing spondylitis.
Burgos-Vargas R; Rojas-Serrano J
J Rheumatol; 2005 Sep; 32(9):1637-40. PubMed ID: 16142852
[No Abstract] [Full Text] [Related]
7. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
[No Abstract] [Full Text] [Related]
8. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
Song IH; Maksymowych WP
Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of anti-TNF-α therapy on sleep problems: A polisomnographic study.
Karatas G; Bal A; Yuceege M; Firat H; Gurcay E; Ardic S; Cakci FA
Int J Rheum Dis; 2018 Jun; 21(6):1263-1269. PubMed ID: 28556500
[TBL] [Abstract][Full Text] [Related]
10. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
Smith N; Gadsby K; Butt S; Deighton C
Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
[No Abstract] [Full Text] [Related]
11. Anti-TNF-alpha therapy for ankylosing spondylitis--a specific or nonspecific treatment?
Dayer JM; Krane SM
N Engl J Med; 2002 May; 346(18):1399-400. PubMed ID: 11986415
[No Abstract] [Full Text] [Related]
12. TNF inhibitors for ankylosing spondylitis in the real world.
McVeigh CM; Bell AL; Cairns AP
Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
[No Abstract] [Full Text] [Related]
13. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.
Hamilton L; Barkham N; Bhalla A; Brittain R; Cook D; Jones G; Mackay K; Marshall D; Marzo-Ortega H; Murphy D; Riddell C; Sengupta R; Siebert S; Van Rossen L; Gaffney K;
Rheumatology (Oxford); 2017 Feb; 56(2):313-316. PubMed ID: 27558584
[No Abstract] [Full Text] [Related]
14. Ankylosing spondylitis associated with primary aldosteronism in a middle-aged woman.
Suh YS; Kim HO; Cheon YH; Jo W; Hong J; Lee SI
Korean J Intern Med; 2017 Mar; 32(2):374-377. PubMed ID: 26842104
[No Abstract] [Full Text] [Related]
15. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
[TBL] [Abstract][Full Text] [Related]
16. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
[TBL] [Abstract][Full Text] [Related]
17. Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure.
Benucci M; Damiani A; Bandinelli F; Grossi V; Infantino M; Manfredi M; Gobbi FL; Sarzi-Puttini P; Atzeni F
Isr Med Assoc J; 2018 Feb; 20(2):119-122. PubMed ID: 29431309
[No Abstract] [Full Text] [Related]
18. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
Henderson C; Davis JC
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):211-8. PubMed ID: 16932687
[TBL] [Abstract][Full Text] [Related]
20. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
